Intended for healthcare professionals

Letters Covid vaccine efficacy

Money, market, media, and vaccine nationalism in the pandemic era

BMJ 2021; 372 doi: https://doi.org/10.1136/bmj.n630 (Published 05 March 2021) Cite this as: BMJ 2021;372:n630
  1. Padmanabhan Badrinath, consultant in public health medicine and associate clinical lecturer12
  1. 1Directorate of Public Health, Endeavour House, Suffolk County Council, Ipswich IP1 2BX, UK
  2. 2University of Cambridge, Cambridge, UK
  1. p.badrinath{at}suffolk.gov.uk

The BMJ reports preliminary efficacy data from the phase III trial of the Novavax vaccine.1 In this pandemic era, the rules of scientific publication and peer review have been rewritten, and important studies are reported not through peer reviewed publications but through press releases to the market. This is true for both Novavax2 and Johnson & Johnson3 vaccines, which have the potential to make money for shareholders or increase investment. Novavax proclaimed: “NVX-CoV2373 is the first vaccine to …

View Full Text

Log in

Log in through your institution

Subscribe

* For online subscription